In addition, BMP agonists that are engineered to prevent interactions with Grem1, as has been performed for Noggin [59], or BMP-mimetic small-molecule drugs [60, 61], could be beneficial in the treatment of breast cancer patients with high Grem1 expression. Here, GREM1 is linked to breast carcinoma.